UCB has standardised its global pharmacovigilance operations on Veeva Safety Suite as part of a wider effort to streamline safety processes and increase automation across its organisation.

The pharmaceutical company is using the platform to manage adverse event reporting, safety documentation, signal detection and regulatory data sharing through a single system.

According to Veeva Systems, the implementation is intended to improve operational efficiency, strengthen oversight of safety activities and support faster processing of safety cases.

Jonas Maselis, head of digital technology, patient safety at UCB, said: “Moving our teams onto Veeva Safety Suite is a core step in UCB’s safety transformation, helping streamline global and local workflows with a single source of truth for safety data.

“As we use automation to drive low-touch case processing, our strategic partnership with Veeva positions us well for what’s next.”

Under the agreement, UCB will deploy multiple applications within the Veeva Safety Suite platform, including Veeva Safety for adverse event management, Veeva SafetyDocs for safety-related documentation, Veeva Safety Workbench for safety data analysis and reporting, and Veeva Safety Signal for signal detection activities.

The implementation also includes integration between Veeva’s safety and regulatory systems through the Veeva Safety-RIM Connection, which enables product information to be shared automatically between regulatory and pharmacovigilance functions.

Pharmacovigilance teams are increasingly adopting digital platforms and automation tools as the volume and complexity of safety data continue to grow across global markets.

John Lawrie, vice president, Veeva Safety, said: “UCB is building a foundation powered by Veeva Safety Suite to simplify and standardize their global pharmacovigilance function.

“With a unified and connected approach, UCB is enhancing global compliance and driving advanced automation to deliver safe and effective medicines to patients.”

Financial terms of the agreement were not disclosed.